Media Monitoring Tools 2026: Automating Reputation Management and Press Analysis
In today’s fast-paced digital landscape, reputational crises and information attacks unfold in minutes. A single negative mention in an online publication or a coordinated fake news campaign can inflict immediate damage on a brand. That is why automated monitoring of the press and digital platforms has become a cornerstone of both corporate security and PR strategy.
Sebela Reports Positive Phase 3 Data for Tegoprazan in GERD Treatment
Sebela Pharmaceuticals has reported successful Phase 3 results for tegoprazan, a potassium-competitive acid blocker designed to treat non-erosive reflux disease. Data presented at the American College of Gastroenterology 2026 meeting show the drug significantly reduces both heartburn and regurgitation compared to placebo in patients with chronic symptoms.
Celltrion to Unveil New ZYMFENTRA Data at ACG 2026
Celltrion USA will present fresh clinical findings on ZYMFENTRA at the American College of Gastroenterology 2026 Annual Scientific Meeting in Nashville. The upcoming presentations highlight the drug's performance in Crohn's disease and ulcerative colitis, specifically addressing treatment interruptions and patient outcomes in ileum-dominant cases.
Investors Face November Deadline in Celsius Holdings Securities Suit
Investors who purchased Celsius Holdings, Inc. securities between February 21, 2025, and June 3, 2026, face a November 3, 2026, deadline to apply as lead plaintiff in a pending class action lawsuit. The litigation alleges the company misled shareholders regarding health risks associated with its Alani Nu product line.
AbbVie Unveils New Clinical Data for IBD Treatments at ACG Meeting
Patients with inflammatory bowel disease may see improved clinical outcomes following new Phase 3 trial results for SKYRIZI and RINVOQ, according to data presented by AbbVie at the American College of Gastroenterology 2026 Annual Scientific Meeting in Nashville this week.